Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Stock Short Interest Climbs 191.6%

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totaling 195,736 shares, a growth of 191.6% from the September 30th total of 67,129 shares. Based on an average daily volume of 515,895 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.2% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Stock Down 12.3%

HKPD traded down $0.27 on Friday, reaching $1.92. 27,059 shares of the company traded hands, compared to its average volume of 68,326. The firm has a fifty day simple moving average of $3.17 and a two-hundred day simple moving average of $9.45. The company has a current ratio of 3.86, a quick ratio of 3.75 and a debt-to-equity ratio of 0.01. Hong Kong Pharma Digital Technology has a one year low of $1.63 and a one year high of $29.00.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.82) EPS for the quarter. The firm had revenue of $3.15 million for the quarter.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.